As of late 2025, Medicare does cover Journavx for some beneficiaries, but only a small share of Part D plans include it on their formularies. Roughly 10.7% of Medicare enrollees had plan coverage for the non-opioid pain drug, compared with about 62% of commercial enrollees and nearly 94% of Medicaid enrollees.1GoodRx. How Much Journavx Costs Without Insurance If your plan is one of the ones that doesn’t cover it, the manufacturer runs a savings program that can bring the price down to $30 per fill through June 30, 2026.
Check Your Specific Plan First
Part D coverage is set plan by plan, not by Medicare centrally. You can look up whether your plan covers Journavx by entering your ZIP code at journavxhcp.com/coverage.2Journavx HCP. Journavx Coverage Information
One significant expansion took effect May 1, 2026, when Vertex Pharmaceuticals reached an agreement with a major pharmacy benefit manager to add Part D coverage for roughly 10 million lives.3Vertex Pharmaceuticals. Vertex Reports First Quarter 2026 Financial Results Even so, most Part D plans still do not list the drug.
What You Pay If Your Plan Does Cover It
If Journavx is on your plan’s formulary, standard Part D cost-sharing applies, and everything you spend out of pocket counts toward the Part D annual cap. For 2026, that cap is $2,100, up from $2,000 in 2025.4UnitedHealthcare. Medicare Part D Changes Once your combined spending on deductibles, copays, and coinsurance for all covered Part D drugs reaches that limit, you pay $0 for covered prescriptions for the rest of the year. You can also elect to spread those out-of-pocket costs into monthly installments of roughly $175 instead of absorbing a large bill up front.5MedicareResources.org. How Will the Inflation Reduction Act Affect Medicare Enrollees
Expect restrictions even when a plan does cover the drug. Typical utilization controls include a quantity limit of 29 tablets over 14 days every three months for the initial fill, with prior authorization required for refills.2Journavx HCP. Journavx Coverage Information At least one formulary places the drug on Tier 4, a non-preferred brand tier that typically carries higher cost-sharing, and imposes both quantity limits and prior authorization.6Formulary Navigator. Journavx Oral Tablet 50 mg Formulary Search Some plans also require step therapy. Kaiser Foundation Health Plan of the Northwest, for example, lists Journavx as non-formulary and covers it only when narrow clinical criteria are met, including failure of over-the-counter acetaminophen and lidocaine, inability to take NSAIDs due to specific contraindications, and the patient not being a candidate for opioids due to opioid use disorder.7Kaiser Permanente. Journavx Coverage Criteria
Of the 10.7% of Medicare enrollees with coverage, 5.6% faced prior authorization and 1.7% were subject to step therapy.1GoodRx. How Much Journavx Costs Without Insurance
What You Pay If Your Plan Doesn’t Cover It
Journavx has a list price of about $15.50 per tablet, or roughly $690 for a five-day course. Without coverage, that is the sticker you face at the pharmacy counter.
The 2026 Patient Savings Program
Vertex’s JOURNAVX+you program includes a 2026 Patient Savings Program built specifically for people with government-sponsored insurance, including Medicare, whose plans do not cover the drug. Eligible patients can pay as little as $30 per fill for up to 61 tablets (a 30-day supply), with the manufacturer covering up to $1,000 per fill. Total assistance is capped at $2,000 every 365 days, and the program runs through June 30, 2026.8Journavx. Support Program Brochure for Patients
To use it, present the Journavx Savings Card at a retail pharmacy. The pharmacist submits the claim to your Medicare plan first. If the claim is rejected with one of three denial codes — product not covered (70), prior authorization required (75), or product not on formulary (MR) — the pharmacist can then process the claim through the savings program as a secondary payer.9Journavx HCP. Journavx HCP Support No enrollment is required. You can download the savings card at JOURNAVX.com/support, or call 1-833-589-7246 with questions.
One caveat matters for Part D math: amounts paid through this savings program do not count toward your Medicare Part D true out-of-pocket (TrOOP) spending.10Journavx. Journavx Savings Card Terms Using the program won’t move you any closer to the $2,100 annual cap.
If prior authorization is the obstacle rather than a flat formulary exclusion, your prescriber can submit a prior authorization request or formulary exception, using the manufacturer’s prior authorization toolkit for supporting documentation.11Journavx HCP. Journavx Prior Authorization Toolkit
The Standard Copay Card Does Not Apply
Vertex also runs a Co-pay Assistance Program that can reduce costs to $30 per fill for commercially insured patients. That program explicitly excludes anyone with Medicare, Medicaid, or other government-funded insurance.12Journavx. Journavx Terms and Conditions The exclusion exists because federal anti-kickback rules generally bar manufacturers from subsidizing copays for government program beneficiaries. If you are on Medicare, the 2026 Patient Savings Program described above is the pathway available to you, not the standard copay card.
Journavx in a Surgical Setting Is a Separate Pathway
Part D covers Journavx when you fill it at a pharmacy. If Journavx is instead administered to you during a procedure in a hospital outpatient department or ambulatory surgical center, Medicare Part B handles payment through a different mechanism created by the NOPAIN Act.
CMS approved Journavx for separate payment under that program with an effective date of January 23, 2026, retroactive to that date.3Vertex Pharmaceuticals. Vertex Reports First Quarter 2026 Financial Results The program is temporary and is scheduled to run through December 31, 2027.13Centers for Medicare and Medicaid Services. Non-Opioid Treatments for Pain Relief This pathway affects what the facility is paid, not whether your Part D plan covers an outpatient prescription.
Why Medicare Coverage Lags and What May Change
The coverage gap between Medicare and other insurance is largely driven by price. Journavx costs about $15.50 per tablet; generic opioids cost a few dollars. Part D plans, which operate under tight budgets and negotiate through pharmacy benefit managers, have been slow to grant broad formulary access without pricing arrangements that justify the higher upfront expense.
Two things could shift that. The Alternatives to PAIN Act, reintroduced in the 119th Congress as S. 475 and H.R. 1227, would require that Medicare Part D beneficiaries pay no more for a non-opioid pain prescription than they would for an opioid prescription. It has bipartisan sponsorship and 36 Senate cosponsors as of May 2026, but remains in committee with no vote scheduled.14Congress.gov. S.475 – Alternatives to PAIN Act Separately, in April 2026, 116 organizations and 44 lawmakers urged CMS to use its existing administrative authority to push Part D plans toward better access to FDA-approved non-opioid pain medications.15Voices for Non-Opioid Choices. Alternatives to PAIN Act
Until one of those moves — or more plan-level agreements like the May 2026 PBM deal — plays out, most Medicare beneficiaries prescribed Journavx will need to rely on the manufacturer’s savings program or press for a formulary exception.